Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We studied the survival period in two groups of patients with endometrial adenocarcinoma treated at the Chair B Institute of Gynecology and Obstetrics. The first series includes 30 of the 52 patients treated from 1976 to 1979. The second series includes 81 patients treated from 1980 to 1986. Lymph nodal positivity was present in 5 cases out of 30 patients belonging to Group I: all the interested lymph nodes were in the pelvic areas. Lymph nodal metastases were, instead, present in 10 cases as regard patients of Group II. Pelvic lymph nodes were involved in all the cases; in 5 of them also the paraaortic nodes were involved.
 ...
PMID:Hormonal and surgical treatment of endometrial adenocarcinoma: actuarial survival. 339 Nov 93

Six female patients, all with dermatomyositis (DM) and malignancy, have been evaluated and followed over a period of up to 6 years. Five patients had malignancy prior to the diagnosis of DM. Two of these five patients had uterine endometrial adenocarcinoma and another two patients had cervical carcinomas (one each adenocarcinoma and squamous cell carcinoma), and one had adenocarcinoma of the breast. In these five patients there was no evidence of malignancy at the time of diagnosis of DM. One of these five patients had an additional primary malignancy (adenocarcinoma of the breast) which complicated her course. An ovarian adenocarcinoma was present in the sixth patient. The ovarian carcinoma was discovered because of progressive cutaneous disease, and resection and chemotherapy led to a partial control of the DM. The patient with adenocarcinoma of the cervix developed metastases which were discovered when the DM became resistant to therapy. Although DM can parallel the course of a malignant disease, this was not generally the case in this group of patients.
 ...
PMID:Dermatomyositis and female malignancy. 372 95

A case of metastatic uterine papillary serous carcinoma with a complete response to chemotherapy is reported. The patient presented with vaginal, pelvic, and lymph node metastases 11 months after primary surgical resection was performed. A complete response to cyclophosphamide, Adriamycin (doxorubicin), and cisplatin was achieved. In this histologic pattern of endometrial adenocarcinoma, which behaves clinically like epithelial ovarian cancer, combination chemotherapy can offer significant response and palliation.
 ...
PMID:Uterine papillary serous carcinoma. Complete response to combination chemotherapy. 404 Apr 19

From January 1960 to June 1974, 71 patients with a postsurgical relapse of endometrial adenocarcinoma have been referred to the Radiology Institute of the University of Florence. Eleven patients showed hematogenous metastases; the remaining 60 cases showed locoregional relapses and were treated with radiotherapy. Forty-eight patients, whose relapse was localized to the pelvis, vagina, inguinal nodes or perineal scar, were treated with a radical aim (4,500-6,000 rad in 5-6 weeks); the treatment was palliative in 12 cases with abdominal extrapelvic relapse. The therapeutic response was not evaluated in 8 patients lost to follow-up shortly after the treatment. In the cases treated with a radical scope, a complete regression was attained in 22 of 43 (51%); a survival rate of 16 of 43 (37%) was attained at 5 years. In 9 cases treated with a palliative aim, only subjective remission was attained, and no patient was alive one year after the therapy. The most favorable therapeutic response was attained in the vaginal relapses (50% survivors at 5 years) and the cases with a late recurrence (more than 3 years) after the initial surgery. No definite correlation was found between the prognosis of the relapse and the histological grading of the primary tumor.
 ...
PMID:Salvage with radiotherapy of postsurgical relapses of endometrial cancer. 615 57

The coexistence of carcinoma in the endometrium and ovary is a relatively uncommon but not rare occurrence. In general it has not been possible to determine which, if any, of these tumors represent metastases from endometrium or ovary or separate primary neoplasms, and gynecologists are unable to agree upon appropriate therapy. Twenty-four women with synchronous carcinomas of the ovary and endometrium in whom disease was confined to the pelvis, diagnosed at the Milton S. Hershey Medical Center between 1970 and 1982, were identified. Thirteen women had typical endometrial adenocarcinoma and endometrioid carcinoma of the ovary (Group A), two had unusual variants of endometrial carcinoma and a similar appearing tumor in the ovary (Group B), and nine had typical endometrial adenocarcinoma with carcinomas in the ovary of differing histologic appearance (Group C). There was no significant difference in survival between women in Groups A and C (77 and 56%, respectively, mean follow-up approximately 40 months). However, deep myometrial invasion (outer third) provided a statistically significant indicator of poor prognosis (77% with deep invasion vs 17% with superficial invasion recurred or died of disease P less than 0.05, chi 2 test).
 ...
PMID:Synchronous carcinomas of the uterine corpus and ovary. 650 Mar 75

Nineteen patients with recurrent endometrial carcinoma and one patient with Stage IV endometrial carcinoma not previously treated with chemotherapy were treated with a combination of doxorubicin and cisplatin. The dose schedule was doxorubicin, 50 mg/m2 on day 1, and cisplatin, 50 mg/m2 with hyperhydration on day 1, with a new course every 4 weeks. Objective response 60% was obtained in 12 out of 20 patients (two with complete remission and 10 with partial remission). Furthermore, four patients had stationary disease. The two patients with complete remission both had distal vaginal metastases, and they are still alive after greater than 21 and greater than 40 months. The median survival period for those with partial remission was greater than 11 months (range of 4 to 26); for those with stationary disease, 7 months (range of 4 to 10), and for those with progressive disease, 4 months (range of 3 to 7). The response rate was higher for well-differentiated tumors. No serious side effects were noticed. To our knowledge no other reports have been published so far with the use of the same regimen in patients with recurrent endometrial adenocarcinoma with no prior chemotherapy. We find the objective response rate, the survival time, and the quality of life for the responding patients in our study so encouraging that we shall continue with a larger trial.
 ...
PMID:Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. 653 67

A case is reported of late cutaneous and muscular metastases of a uterine leiomyosarcoma following an initial simultaneous presentation with an endometrial adenocarcinoma. Such behaviour is discussed in view of the prognostic features of the original sarcoma.
 ...
PMID:Late cutaneous and muscular metastases of a uterine leiomyosarcoma after an initial simultaneous presentation with an adenocarcinoma. 663 9

Survival after treatment of stage I endometrial adenocarcinoma was studied in a material of 111 patients, median follow-up period 6 years. Routine treatment was preoperative intrauterine and vaginal radium followed, in 6 weeks, by total hysterectomy and bilateral salpingo-oophorectomy. The 5-year corrected survival after treatment by operation and/or irradiation was 93%, after irradiation alone 87%. A significantly better survival was found in stage Ia (95%) than in stage Ib (83%) and also in patients with grade 1 tumors (97%) than in those with grade 3 tumors (71%). 21% of the patients had a residual endometrial tumor after preoperative radium, and among them survival was significantly lower than in patients without residual tumor. The recurrence rate was 11.7%. Vaginal metastases did not occur. Our routine treatment afford satisfactory results in stage I, grade 1 and 2. However, supplementary treatment must be recommended in the case of grade 3 tumors, of myometrial deep invasion, and of residual tumor following preoperative radium therapy.
 ...
PMID:Adenocarcinoma of the endometrium stage I. Treatment, survival and recurrence. 672 Feb 56

The ability to predict myometrial invasion by endometrial adenocarcinoma is useful for preoperative treatment purposes. The presence of stromal invasion is one possible method of predicting myometrial invasion, but criteria for the presence of stromal invasion have been lacking. Recently, criteria for its detection were proposed. We evaluated the validity of the proposed criteria in two conditions: (1) atypical hyperplasia (119 cases) and (2) endometrial adenocarcinoma Stage I, grade 1 (83 cases). Adenocarcinoma without stromal invasion according to the criteria of Kurman and Norris was present in 43 cases and adenocarcinoma with stromal invasion was present in 40 cases. This series demonstrated the ability of prehysterectomy endometrial sampling to predict the probability of myometrial penetration. In addition, none of our patients without stromal invasion in the resected uterus had myometrial penetration and no metastases have occurred. In those showing stromal invasion in the excised uterus, the myometrium was invaded in 34 of 51 cases (67%). Since myometrial penetration was not present when there was no stromal invasion in the resected uterus, stromal invasion deserves further evaluation and should be considered in future classification of endometrial adenocarcinoma.
 ...
PMID:Stromal invasion in endometrial adenocarcinoma. 672 Jul 60

A prospective trial was initiated in 1972 utilizing Depo-Provera in women with metastatic or recurrent endometrial adenocarcinoma to evaluate if the objective response and survival would be significantly improved in comparison to patients previously treated with Delalutin at a similar dose. One hundred fourteen patients were included in the study: 70 received Delalutin and 44 Depo-Provera. There was no significant increase in the objective response or survival between the Delalutin or Depo-Provera patients. Of the 114 patients, 15.8% achieved an objective response, with 7.0% being complete responders. There was no significant increase in objective response to Delalutin or Depo-Provera in relationship to the size of the tumor masses, the number of metastases, site of metastases, histologic grade of the primary, histologic grade of recurrence or metastases, or prior radiation therapy. The only significant correlate was that patients whose disease recurred 3 or more years after the initial therapy had a significant (P = 0.01) increase in response (33.3%) compared to those with recurrence less than 3 years after their original treatment (8.3%).
 ...
PMID:Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. 698 33


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>